Please login to the form below
ViraTherapeutics
This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.
Boehringer links up with Trutino for cancer R&D
That includes the takeover of oncolytic virus specialist ViraTherapeutics at the end of 2018, which is focused on the latter’s lead candidate VSV-GP, a cancer therapy that works by
Latest news
-
Transgene slumps as viral cancer therapy fails phase 3 trial
Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson
-
Boehringer taps Korea’s Bridge for Ofev follow-up
Last year, Boehringer also acquired the oncolytic virus specialist ViraTherapeutics for 210m and licensed a checkpoint inhibitor from OSE Immunotherapeutics in a deal valued at up to 1bn.
-
Boehringer bolts on another immuno-oncology company
Acquires ViraTherapeutics in a 210m takeover deal. Boehringer Ingelheim’s shopping spree in immuno-oncology has continued with a 210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working ... The privately-held German
-
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal
by ViraTherapeutics in 2016.
-
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal
Boehringer Ingelheim has boosted its position in immuno-oncology by licensing an oncolytic virus therapy developed by Austrian biotech ViraTherapeutics. ... The deal also gives Boehringer an option to acquire ViraTherapeutics outright once phase I
Transgene slumps as viral cancer therapy fails phase 3 trial
Boehringer taps Korea’s Bridge for Ofev follow-up
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
-
Deal Watch September 2016
With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP. .
Deal Watch September 2016
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
